{"filings":[{"id":2226282,"accession_number":"0001493152-26-037574","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-08-13T11:30:16+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.","Decoy20 enrollment discontinued; no participants remain in any clinical study; no active clinical development programs.","June 17, 2026 private placement: 20M shares at $0.60/share, $12.0M gross proceeds; cash+investments $11.6M at June 30.","R&D expenses down 83% to $0.4M (Q2) and $0.9M (six months); G&A down 37% to $1.4M (Q2).","Annual meeting elected David Natan, Tim Ruan, Dr. Johnny Fox Arrowsmith as Class II directors; approved 2026 equity plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1249200,"accession_number":"0001493152-26-029918","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-06-24T20:01:36+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics raises $12M via private placement of 20M shares at $0.60/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$12M gross from sale of 20M shares of common stock at $0.60 per share to non-U.S. accredited investors.","Placement conducted under Regulation S; no commissions or compensation were paid.","Shares are restricted; company must file resale registration statement within 90 days of closing.","Closings occurred on June 17, 2026; registration rights granted to purchasers.","20M new shares represent less than 20% of outstanding shares prior to the private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":889200,"accession_number":"0001493152-26-027499","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-06-05T20:30:44+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics announces resignation of two directors and COO; COO to serve as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David E. Lazar and Avraham Ben-Tzvi resigned from all director positions and committees effective June 5, 2026.","Walt A. Linscott resigned as COO effective June 1, 2026, and will serve as consultant under a consulting agreement.","Resignations were not due to any disagreement with the company's operations, policies, or practices.","No replacements for directors or COO were announced; CEO Junyi Dai remains in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452719,"accession_number":"0001493152-26-023344","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-05-15T12:00:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).","Cash and equivalents fell to $1.5M from $8.5M at Dec 2025; company needs to raise additional capital.","R&D expenses dropped 82% to $0.5M due to Phase 1 clinical cost decrease and headcount reductions.","Executive management transition underway; reassessing development priorities and Decoy platform.","Preferred stock conversion completed during Q1 2026; all Series AA and AAA shares converted to common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96311,"accession_number":"0001493152-26-018954","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K/A","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Matthew McMurdo Resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim Ruan, 40, CFO of Ocumension Therapeutics and former Executive Director at Goldman Sachs, appointed as Class II director.","Dr. Johnny Fox Arrowsmith (Yi Zhang), 48, partner at JunHe and registered patent attorney, appointed as Class II director.","Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement with company.","Each new director receives annual cash retainer of $30,000, payable quarterly, plus expense reimbursement and indemnification.","Ruan appointed to Audit Committee; Arrowsmith appointed to Nominating Committee. New directors effective April 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96313,"accession_number":"0001493152-26-018608","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics appoints Tim Ruan and Dr. Yi Zhang to board; Matthew McMurdo resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Tim Ruan as Class II director and Audit Committee member; qualifies as audit committee financial expert.","Appoints Dr. Yi Zhang as Class II director and Nominating Committee member.","Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement.","Annual cash retainer for each new independent director is $30,000, payable quarterly, plus expense reimbursement.","Both new directors are independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96312,"accession_number":"0001493152-26-015079","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.","Yu Ding appointed CFO effective April 1, 2026; brings experience from Grand Auto Service and Hong Kong listed firms.","Qinglai Lu appointed to Board of Directors effective April 8, 2026; deemed independent.","Qinglai Lu also appointed to Audit Committee along with Jerome Jabbour; Matthew McMurdo resigned from Audit Committee.","New CFO Yu Ding has over 20 years experience in financial planning, capital management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110102,"accession_number":"0001493152-26-012372","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.01","1.01","5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.","Purchasers will own 96.2% of diluted shares post-conversion; may be deemed a group under Exchange Act.","Four directors resigned, including co-CEO Jeffrey Meckler; David Lazar resigned as co-CEO but remains on board.","Junyi Dai, 39, appointed CEO and Chairman; previously Managing Director at FLMD Pty Ltd and independent director.","Company to file resale registration statement within 30 days for 2.064M shares underlying Lazar's retained Series AA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110101,"accession_number":"0001493152-26-008326","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["3.03","5.07","5.03","5.01","9.01"],"status":"ready","headline":"Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.","Authorized common stock increased from 200M to 1B shares; reverse stock split authorized at ratio 1:2 to 1:199.","Jerome Jabbour and Matthew McMurdo elected as directors; Mark Gilbert and Michael Newman resigned immediately after meeting.","Stockholders approved stockholder action by written consent and issuance of common stock upon conversion of preferred stock.","Lazar's nominees now constitute majority of nine-member board; company plans to pursue strategic transaction with target company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110100,"accession_number":"0001493152-26-006330","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics reduces warrant exercise prices to $1.75; enters voting agreements ahead of special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company repriced ~913,638 warrants held by certain holders from $8.30-$47.60 down to $1.75.","Board unilaterally reduced exercise prices of remaining ~762,787 warrants to $1.75.","Holders agreed to vote shares in favor of proposals at Feb 26, 2026 special meeting.","New exercise price of $1.75 equals Nasdaq Minimum Price per applicable rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110099,"accession_number":"0001493152-26-002850","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus cuts co-CEO and CSO salaries to $60K/year; director rescinds resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Co-CEO Jeffrey A. Meckler and CSO Michael J. Newman salaries reduced to $60,000 per annum effective Jan 15, 2026.","Director Anthony Maddaluna rescinded his prior resignation and will remain on the Board, including Compensation and Nominating committees.","Salary adjustments are for the remainder of the 2026 calendar year and follow prior employment modifications from Dec 2025.","The reductions are part of a cost-saving measure tied to a securities purchase agreement with investor David E. Lazar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110098,"accession_number":"0001493152-26-001004","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics appoints David Natan to board and audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 8 to 9 members; David Natan appointed as Class II director until 2026 annual meeting.","Natan replaces Avraham Ben-Tzvi as Audit Committee member; Ben-Tzvi to become paid consultant while remaining on board.","Natan was designated by David E. Lazar under securities purchase agreement dated December 22, 2025.","Natan is CPA and CEO of Natan & Associates; also serves on boards of Sunshine Biopharma and FIEE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110097,"accession_number":"0001493152-26-000106","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Three Indaptus Therapeutics directors resign pending stockholder vote on Lazar nominees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Michael Newman, Mark Gilbert, Anthony Maddaluna resigned effective upon approval of David Lazar's nominees at next stockholder meeting.","Resignations not due to any disagreement with Company, management, Board, or committees.","Board changes likely part of ongoing activist or settlement with David Lazar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126658,"accession_number":"0001493152-25-029107","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.","Lazar appointed Chairman and Co-CEO; board adds Avraham Ben-Tzvi; directors Martell and Karah resign.","Special meeting by Mar 31, 2026 to approve conversion, authorized share increase, written consent, reverse split, and Lazar board nominees.","Executive officers modify employment: reduce notice to 10 days, waive severance for stock/cash; CMO Waltzman resigns with $207K bonus.","Issuance under Regulation S exemption; proceeds for operations, severance, working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126657,"accession_number":"0001493152-25-021758","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus reports Q3 loss per share $2.98, cash $5.8M; pauses enrollment pending Decoy20 combo efficacy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.","Completed Safety Lead-In cohort, dosing 6 participants with Decoy20 + tislelizumab; 3 stable disease, 2 remain on study.","Enrollment paused pending additional efficacy evaluation and assessment of next development options.","Raised $2.3M via ATM in September 2025; converted $5.7M promissory notes into stock/warrants in July."],"consensus_eps_estimate":null,"consensus_eps_actual":-18.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143432,"accession_number":"0001493152-25-012630","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.","7 patients dosed in combination with tislelizumab; first 3 evaluable: 1 stable disease, 2 progression.","Raised $5.7M gross proceeds from convertible notes converted to common stock and pre-funded warrants in July 2025.","Monotherapy portion completed; initial combination safety cohort dosing ongoing, with initial data expected later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143431,"accession_number":"0001641172-25-023332","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.","Cash and equivalents $6.2M as of June 30, 2025; expected runway into Q4 2025.","First patient dosed in Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor tislelizumab (TEVIMBRA).","Raised ~$5.7M gross via convertible notes and warrants in June 2025; converted to common stock and pre-funded warrants in July.","Company expects to share initial combination trial data from first cohort later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":-18.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143430,"accession_number":"0001641172-25-021377","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["3.02","5.07"],"status":"ready","headline":"Indaptus Therapeutics completes note conversion and obtains stockholder approval for private placement issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised gross proceeds of approximately $5.7 million in private placement of convertible notes and warrants, closed June 12 and June 30, 2025.","On July 27, 2025, notes automatically converted into 545,598 common shares at $8.3024 per share; issued 1,384,722 warrants exercisable at same price.","Also issued pre-funded warrants for 146,763 shares and placement agent warrants for 83,083 shares to Paulson Investment Company.","At special meeting on July 25, 2025, shareholders approved issuance by 225,534 votes for (95.2%) and 225,161 votes for related-party issuance.","Total votes represented 41.35% of outstanding shares, with quorum achieved; both proposals passed with overwhelming majority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143429,"accession_number":"0001641172-25-019893","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 14, 2025 that closing bid price was ≥$1.00 for 10 consecutive business days (June 27-July 11, 2025).","Previously reported non-compliance on January 31, 2025; had until July 30, 2025 to regain compliance.","Nasdaq considers the bid price deficiency matter now closed.","Regaining compliance removes imminent delisting risk from The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143428,"accession_number":"0001641172-25-017283","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Indaptus raises additional $3.4M via convertible notes and warrants, total $5.7M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second closing of private placement adds $3.4M in convertible notes; aggregate gross proceeds now $5.7M.","Notes bear 6% interest, mature July 28, 2026; convert at 80% of 5-day VWAP (max $11.20).","Warrants for 200% of conversion shares, 5-year term, exercise price equal to the conversion price.","Net proceeds to fund Phase 1b/2 clinical trial, R&D, and working capital.","Paulson Investment Company served as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161611,"accession_number":"0001641172-25-016694","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Indaptus Therapeutics implements 1-for-28 reverse stock split effective June 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1-for-28 effective after market close on June 26, 2025.","Trading on split-adjusted basis begins June 27, 2025; new CUSIP 45339J 204.","Purpose is to regain Nasdaq continued listing compliance and attract institutional investors.","Outstanding shares reduced from ~16 million to ~572 thousand; no change in authorized shares.","Proportionate adjustments made to options, warrants; fractional shares paid in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161610,"accession_number":"0001641172-25-014972","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Indaptus raises $2.3M via convertible notes and warrants; up to $5M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.3M aggregate principal of 6% convertible promissory notes; mature July 28, 2026.","Conversion at 80% of 5-day VWAP, max $0.40; warrants for 200% of conversion shares after approval.","Net proceeds for R&D, Phase 1b/2 trial funding, and general working capital.","Offering may increase to $5M; Paulson Investment Company is exclusive placement agent with 12% fee.","Company must hold special meeting for stockholder approval; note conversion tied to reverse split or 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161609,"accession_number":"0001641172-25-014689","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Indaptus Therapeutics shareholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors: Gilbert, Karah, Martell; each received ~3.4M votes for.","Ratified Haskell & White LLP as independent auditor for FY2025 (7,416,332 for).","Advisory say-on-pay approved: 3,346,942 for, 768,207 against.","Reverse stock split amendment approved (6,777,054 for); ratio 1:5 to 1:28, board discretion.","Approximately 52% of outstanding shares (8,386,348) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161608,"accession_number":"0001641172-25-010098","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Q1 2025: cash burn $5.0M; $3.9M cash; needs capital beyond Q2 2025; Decoy20 combo trial started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.","Net loss per share $0.32 in Q1 2025 vs $0.45 in Q1 2024; R&D expenses $2.8M (up from $1.6M) due to Phase 1 trial costs.","Initiated Phase 1b/2 combination arm of Decoy20 with BeOne's PD-1 inhibitor Tislelizumab; weekly dosing arm concluded after 32 patients.","Patents granted in China, Japan, Israel for Decoy platform; cost-reduction plan implemented to focus on combination study."],"consensus_eps_estimate":-5.1408,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179737,"accession_number":"0001493152-25-010138","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.","Entered $20M equity line with Yorkville in Feb 2025; expects cash runway into Q2 2025.","Phase 1 Decoy20 weekly dosing cohort >20 patients; early stable disease observed.","R&D expense Q4 2024 $2.5M vs $2.0M YoY; full-year $7.2M vs $7.6M.","Clinical supply agreement with BeiGene for tislelizumab combo trial expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179736,"accession_number":"0001493152-25-006052","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Indaptus enters $20M standby equity line with Yorkville; issues 305,960 commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M equity purchase agreement with YA II PN (Yorkville) over 36 months.","Shares sold at 97% of lowest 3-day VWAP; 305,960 commitment shares and $25k fee issued.","Exchange cap 2,823,244 shares (19.99% of outstanding) unless price ≥$0.81722 or shareholder approval.","Terminates prior Lincoln Park Capital purchase agreement from December 2022.","Registration statement required before any advances can be drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179735,"accession_number":"0001493152-25-004428","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Indaptus receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 31, 2025 for non-compliance with minimum bid price of $1.00 per share.","Bid price below $1.00 for 30 consecutive business days triggered the notice.","Has 180 calendar days (until July 30, 2025) to regain compliance.","To cure, closing bid must be at least $1.00 for 10 consecutive business days.","May consider reverse stock split; second 180-day period available if other standards met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179734,"accession_number":"0001493152-25-002145","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Indaptus raises $2.25M in private placement of stock and warrants at $1.065/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2.25M from sale of 2,109,383 shares and warrants to purchase 2,109,383 shares (combined price $1.065/unit).","Warrants exercisable at $0.94, immediately exercisable, five-year term; proceeds for R&D and working capital.","Placement agent Paulson Investment receives 7% fee and warrants for 147,656 shares at $1.175.","Closing expected on or about January 15, 2025; securities unregistered, sold under Rule 506(b).","Company to file resale registration statement within 60 days, effective within 90 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196490,"accession_number":"0001493152-24-047422","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Indaptus Therapeutics prices $2.135M offering of stock and warrants at $1.175/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,817,017 shares of common stock and warrants to buy 1,817,017 shares at $1.175 per unit.","Warrants exercisable at $1.05/share, immediately exercisable, 5-year term; gross proceeds ~$2.135M.","CEO participating, purchasing 42,553 shares and warrants on same terms as other investors.","Funds to be used for R&D, working capital, and general corporate purposes.","Closing expected November 25, 2024; Paulson Investment Company acting as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196489,"accession_number":"0001493152-24-044533","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).","Cash and equivalents $7.4M at Sep 30, 2024, down from $13.4M at Dec 31, 2023; cash runway into Q1 2025.","Clinical supply agreement with BeiGene to combine Decoy20 with tislelizumab (anti-PD-1) for advanced solid tumors.","Phase 1 trial of Decoy20 now allows unrestricted enrollment for weekly dosing at lower dose; well tolerated.","R&D expenses decreased to $1.5M in Q3 2024 from $2.2M YoY; completed $3M registered direct offering in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196488,"accession_number":"0001493152-24-041886","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus partners with BeiGene to test Decoy20 + tislelizumab combo in solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical supply agreement with BeiGene Switzerland GmbH for anti-PD-1 antibody tislelizumab.","Indaptus funds all study costs except BeiGene's product; BeiGene supplies tislelizumab.","Plans to seek FDA approval and begin combination study in 2025 for advanced solid tumors.","Decoy20 is Indaptus' novel immune-response-inducing candidate for cancer therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212803,"accession_number":"0001493152-24-031157","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Q2 net loss $0.47/sh; cash $7.3M; raises $3M in August offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.47 for Q2 2024 vs $0.39 YoY; six-month loss $0.92 vs $0.89.","Cash and equivalents $7.3M at June 30, 2024; raised $3.0M (net ~$2.5M) on August 8 via registered direct offering and private placement.","Phase 1 Decoy20 trial: completed one month of weekly dosing in 3 patients at 3x10^7 dose; single dose at 7x10^7 completed.","Presented Decoy20 data at AACR and ASCO; CSO Michael Newman chaired STING & TLR Summit.","Cash runway expected into Q1 2025 based on current operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212802,"accession_number":"0001493152-24-030671","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Indaptus raises ~$3M in registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.0M from sale of 1,643,837 shares and warrants to purchase same number of shares.","Combined purchase price $1.825 per share and warrant; warrant exercise price $1.70, 5-year term.","CEO participating, purchasing 84,932 shares and warrants on same terms.","Closing expected August 8, 2024; net proceeds for R&D and working capital.","Paulson Investment Company acted as placement agent with 9% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231848,"accession_number":"0001493152-24-023119","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Indaptus stockholders approve amended 2021 stock plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Three Class III directors elected: Roger J. Pomerantz, Michael J. Newman, Jeffrey A. Meckler.","Ratification of Haskell & White LLP as independent auditor for fiscal 2024 approved (3,805,215 FOR vs 469,553 AGAINST).","Amendment to 2021 Stock Incentive Plan approved, increasing shares available and extending evergreen provision (1,881,194 FOR vs 501,555 AGAINST).","Quorum of 4,277,437 shares (50.09% of outstanding) present at June 6, 2024 meeting.","Plan amendment restatement effective June 6, 2024; full text filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231847,"accession_number":"0001493152-24-020966","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.","First patient dosed in multi-dose portion of Phase I trial, evaluating safety of repeat administrations.","Company intends to advance Decoy20 into combination studies with a checkpoint inhibitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231846,"accession_number":"0001493152-24-018161","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.","Initiated multi-dose cohort in Phase 1 trial of Decoy20 after positive preliminary results from second cohort.","Granted key patent in January 2024 to expand intellectual property portfolio.","Accepted for poster presentation at ASCO Annual Meeting on June 1, 2024, highlighting initial Phase 1 Decoy20 data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250137,"accession_number":"0001493152-24-011080","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus to present Decoy10 data at AACR showing immune activation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CSO Michael Newman to present Decoy10 poster at AACR 2024 in San Diego on April 10.","Data confirm mechanism of action: Decoy bacteria activate M1 macrophages, NK, dendritic, Th1 CD4, and CD8 T cells.","Abstract published in AACR journal Cancer Research to support the findings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250136,"accession_number":"0001493152-24-009766","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).","Cash runway expected through Q3 2024; excludes $0.3M ATM proceeds in March 2024.","Positive results from second cohort of Phase 1 Decoy20 trial; initiating multi-dose in solid tumors.","European patent approved in Jan 2024 for platform technology covering viral infection composition.","R&D expenses rose 21% YoY to $7.6M driven by Phase 1 trial and pipeline expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250135,"accession_number":"0001493152-24-008670","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.","Independent Safety Review Committee recommended continuing to multiple doses of Decoy20.","Company has started screening patients for multi-dose safety and efficacy across multiple cancer types.","Animal models demonstrated Decoy20 safety in several multiple-dose schedules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250134,"accession_number":"0001493152-24-003441","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Indaptus amends bylaws to adopt universal proxy rules and exclusive federal forum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws effective Jan 22, 2024, addressing universal proxy rules (Rule 14a-19 compliance).","Enhanced disclosure requirements for stockholder director nominations and business proposals.","Prohibits stockholder from submitting more director nominees than seats for election.","Requires proxy cards other than white for stockholders soliciting proxies.","Establishes federal district courts as exclusive forum for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267675,"accession_number":"0001493152-23-039517","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.","Net loss per share $0.47 for Q3 2023 versus $0.42 year ago; R&D expense $2.2M (up $0.6M YoY).","Decoy20 Phase 1 first cohort: all four patients maintain stable disease; first patient dosed in second cohort.","Roger Waltzman, M.D. appointed Chief Medical Officer effective August 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267674,"accession_number":"0001493152-23-039445","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.","Decoy20 induced transient expression of over 50 biomarkers associated with innate/adaptive anti-tumor immune responses.","Adverse events generally tolerable, resolved within 30 minutes to 3 days; drug cleared from blood in 30-120 minutes.","Peak cytokine/chemokine induction ~4-24 hours, returning to baseline by 24-48 hours, avoiding prolonged toxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267673,"accession_number":"0001493152-23-038800","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus reports Phase 1 interim data for Decoy20: biomarker activation & transient AEs in first cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim data from first cohort (n=4) of Phase 1 INDP-D101 trial for Decoy20, dosed at 7x10^7 killed bacteria via 1-hour IV infusion.","Treatment-related AEs included changes in hemodynamic parameters, transaminase elevations, lymphopenia; all resolved within 30 min to 3 days.","Transient activation of innate and/or adaptive immune biomarkers observed in all patients as of Aug 31, 2023.","Company to present full interim data at SITC 38th Annual Meeting on November 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284888,"accession_number":"0001493152-23-028054","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Q2 2023 cash $19.7M, Phase 1 trial advances; CMO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $19.7M as of June 30, 2023; runway into Q2 2024.","Phase 1 trial (Decoy20) completed first cohort, authorized to advance to second; evidence of immune activation.","Appointed Roger Waltzman, M.D. as Chief Medical Officer, effective Aug 7, 2023.","Q2 2023 net loss per share $0.39 vs $0.46 prior year; G&A down to $2.0M.","Patent allowances in Brazil and India expanded IP protection to 32 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284887,"accession_number":"0001493152-23-027463","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Indaptus completes first Decoy20 cohort; starts second cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.","Other adverse events (chills, fatigue, vomiting, fever) were grade 1-2 and resolved quickly.","Immune activation observed via transient expression of cytokines/chemokines associated with innate and adaptive pathways.","Second cohort initiated after Safety Review Committee review per protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304680,"accession_number":"0001493152-23-019073","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Indaptus Therapeutics announces 2023 annual meeting voting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,469,519 shares (~53% of outstanding) represented at May 25, 2023 meeting.","William B. Hayes (2,452,279 for) and Anthony Maddaluna (2,544,652 for) elected as Class II directors.","Ratification of Haskell & White LLP as auditor for FY2023: 4,446,392 for, 22,167 against, 960 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304679,"accession_number":"0001493152-23-016267","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.","Cash and equivalents $21.7M at March 31, 2023, down from $26.4M at Dec 31, 2022; cash runway into Q2 2024.","First patient dosed in Phase 1 trial of Decoy20 for solid tumors in March 2023; three trial sites activated.","Patent allowances in Brazil and India bring IP protection to 32 countries for Decoy platform.","Robert Martell, M.D., Ph.D. elected to Board of Directors in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324236,"accession_number":"0001493152-23-008636","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Indaptus appoints Walt Linscott as COO; sets 2023 annual meeting for May 25","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Walt Linscott, previously Chief Business Officer, appointed COO effective March 22, 2023.","Robert Martell, M.D., Ph.D. appointed to Board's Science and Technology Committee.","Annual meeting set for May 25, 2023; stockholder proposals due by April 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324235,"accession_number":"0001493152-23-008009","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).","Cash and marketable securities $26.4M as of Dec 31, 2022; runway into Q2 2024.","First patient dosed in Phase 1 Decoy20 trial for solid tumors in March 2023; three sites activated.","Net cash used in operations $13.1M for FY2022 vs $11.3M in FY2021.","Robert Martell, M.D., Ph.D. elected to Board in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324234,"accession_number":"0001493152-23-004613","cik":1857044,"company_name":"Indaptus Therapeutics, Inc.","ticker":"INDP","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Indaptus appoints Robert Martell, M.D., Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to nine; Martell appointed Class I director effective Feb 13, 2023.","Annual retainer of $50,000 for Board service; standard indemnification agreement.","Received initial option for 20,000 shares at $1.71/share (fair market value on grant date).","Annual equity award up to $75,000 value (Black-Scholes) vesting on first anniversary or upon change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":156840607.31102362,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-14T23:59:59+00:00|324234"}